Pyrimidines or their pharmaceutically acceptable salts thereof
申请人:MITSUI PHARMACEUTICALS, INC.
公开号:EP0305184A1
公开(公告)日:1989-03-01
Compounds of formula
where X is -NR¹R² or SR⁴; Y is amino optionally substituted by alkyl; Z is methyl substituted by alkoxy carbonyl or alkoxycarbonyl or Y and Z together may form a divalent group -X-Y- of formula
. The compounds are useful in the treatment if neurological diseases of the pheripheral and central nervous systems of animals.
式中化合物
其中 X 是-NR¹R²或 SR⁴;Y 是任选被烷基取代的氨基;Z 是被烷氧羰基或烷氧羰基取代的甲基,或 Y 和 Z 可共同形成式中的二价基团-X-Y-。
.这些化合物可用于治疗动物外周和中枢神经系统的神经疾病。
Pyrimidines and their pharmaceutical acceptable salts, and their use as medicines
申请人:MITSUI PETROCHEMICAL INDUSTRIES, LTD.
公开号:EP0379806A2
公开(公告)日:1990-08-01
2,6-di-, 2,4,6-, 2,5,6-tri- or 2,4,5,6-tetra-substituted pyrimidines, and 2,6-di-substituted pyridines. These compounds are useful for treatment of neurological deseases.
PYRIMIDINE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
申请人:MITSUI PETROCHEMICAL INDUSTRIES, LTD.
公开号:EP0489925A1
公开(公告)日:1992-06-17
A pyrimidine compound represented by general formula (I), pharmaceutically acceptable salts thereof, and a drug containing the same for treating neural diseases, wherein X represents substituted or cyclic amino and Y represents substituted amino or substituted carbonyl. These compounds have activities of promoting the growth of nerve cells and the formation and extension of neurites, so that they are useful in treating various neural diseases.
通式(I)代表的嘧啶化合物、其药学上可接受的盐类以及含有相同成分的用于治疗神经疾病的药物,其中 X 代表取代的或环状氨基,Y 代表取代的氨基或取代的羰基。这些化合物具有促进神经细胞生长以及神经元的形成和延伸的活性,因此可用于治疗各种神经疾病。
Pyrimidines and their pharmaceutical acceptable salts and their use as medicines
申请人:MITSUI PETROCHEMICAL INDUSTRIES, LTD.
公开号:EP0612746A1
公开(公告)日:1994-08-31
2-Substituted pyrrelo[2,3-d]pyrimidines are useful for the treatment of neurological diseases.